C4 glomerulopathy screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

There is insufficient information to recommend routine screening for C4 glomerulopathy.

Screening

There is insufficient evidence to recommend routine screening for C4 glomerulopathy. Quantifying CD46 expression on peripheral blood mononuclear cells for mutations and genes that encrypt complement factors include^[1]^[2]:

CFH
CFI
CD46 (encoding CD46)
CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5
Genes that encode complement activators
CFB
C3

References

↑ Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G; et al. (2017). “C4 Nephritic Factors in C3 Glomerulopathy: A Case Series”. Am J Kidney Dis. 70 (6): 834–843. doi:10.1053/j.ajkd.2017.07.004. PMC 5701858. PMID 28838767.
↑ Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ; et al. (2016). “High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies”. J Am Soc Nephrol. 27 (4): 1245–53. doi:10.1681/ASN.2015040385. PMC 4814193. PMID 26283675.

Template:WH Template:WS

[pmid28838767-1] Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G; et al. (2017). “C4 Nephritic Factors in C3 Glomerulopathy: A Case Series”. Am J Kidney Dis. 70 (6): 834–843. doi:10.1053/j.ajkd.2017.07.004. PMC 5701858. PMID 28838767.

[pmid26283675-2] Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ; et al. (2016). “High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies”. J Am Soc Nephrol. 27 (4): 1245–53. doi:10.1681/ASN.2015040385. PMC 4814193. PMID 26283675.

[1]

[2]